Aurobindo Pharma Income Statement

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021
Operating Revenue	333,600	317,237	290,019	248,554	234,555	247,746
Other Revenue	-1,781	-	-	-	-	-
Revenue	331,819	317,237	290,019	248,554	234,555	247,746
Revenue Growth (YoY)	7.31%	9.38%	16.68%	5.97%	-5.33%	7.26%
Cost of Revenue	139,448	134,839	129,857	116,417	104,499	101,898
Gross Profit	192,371	182,399	160,162	132,137	130,056	145,849
Selling, General & Admin	50,502	45,470	40,434	36,560	35,751	36,576
Other Operating Expenses	73,219	70,693	60,894	58,083	49,976	54,183
Operating Expenses	140,579	132,074	116,247	107,018	96,992	101,313
Operating Income	51,791	50,324	43,915	25,119	33,064	44,536
Interest Expense	-3,839	-4,404	-2,681	-1,290	-368.4	-595.7
Interest & Investment Income	3,564	3,564	2,883	1,485	349.7	223.7
Earnings From Equity Investments	-282.4	-316.9	-171.6	-116.7	-312.5	-553.6
Currency Exchange Gain (Loss)	496.9	-226.5	387.8	-	699.6	1,036
Other Non Operating Income (Expenses)	725.7	1,962	1,672	974.6	1,028	1,521
EBT Excluding Unusual Items	52,456	50,903	46,006	26,173	34,461	46,167
Merger & Restructuring Charges	-	-	-986.6	-	-	-
Impairment of Goodwill	-96.2	-96.2	-27.4	-70.3	-	-4,349
Gain (Loss) on Sale of Investments	335.3	335.3	1	-	290.8	-
Gain (Loss) on Sale of Assets	-	-	234.9	132.3	-400.2	-1,411
Asset Writedown	-600.2	-600.2	-2,834	-239.6	-1,922	-
Other Unusual Items	-532	121.3	1,407	130.1	1,298	33,029
Pretax Income	51,563	50,663	43,800	26,125	33,727	73,436
Income Tax Expense	16,714	15,827	12,110	6,849	7,256	20,098
Earnings From Continuing Operations	34,850	34,836	31,690	19,277	26,471	53,338
Minority Interest in Earnings	20	23.1	40	-1.5	10.4	10.2
Net Income	34,870	34,859	31,730	19,275	26,482	53,348
Net Income to Common	34,870	34,859	31,730	19,275	26,482	53,348
Net Income Growth	-0.12%	9.86%	64.62%	-27.21%	-50.36%	87.51%
Shares Outstanding (Basic)	581	583	586	586	586	586
Shares Outstanding (Diluted)	581	583	586	586	586	586
Shares Change (YoY)	-0.50%	-0.52%	-	-	-	-
EPS (Basic)	60.04	59.81	54.15	32.90	45.20	91.05
EPS (Diluted)	60.04	59.81	54.15	32.90	45.19	91.05
EPS Growth	0.38%	10.44%	64.62%	-27.21%	-50.37%	87.51%
Free Cash Flow	-	19,568	-3,458	-170.5	29,636	18,911
Free Cash Flow Per Share	-	33.57	-5.90	-0.29	50.58	32.27
Dividend Per Share	-	-	4.500	3.000	9.000	4.000
Dividend Growth	-	-	50.00%	-66.67%	125.00%	33.33%
Gross Margin	57.98%	57.50%	55.23%	53.16%	55.45%	58.87%
Operating Margin	15.61%	15.86%	15.14%	10.11%	14.10%	17.98%
Profit Margin	10.51%	10.99%	10.94%	7.75%	11.29%	21.53%
Free Cash Flow Margin	-	6.17%	-1.19%	-0.07%	12.63%	7.63%
EBITDA	66,858	64,817	57,641	36,344	43,114	53,947
EBITDA Margin	20.15%	20.43%	19.88%	14.62%	18.38%	21.77%
D&A For EBITDA	15,067	14,492	13,726	11,225	10,050	9,411
EBIT	51,791	50,324	43,915	25,119	33,064	44,536
EBIT Margin	15.61%	15.86%	15.14%	10.11%	14.10%	17.98%
Effective Tax Rate	32.41%	31.24%	27.65%	26.21%	21.52%	27.37%
Revenue as Reported	337,182	323,456	295,593	251,460	237,758	251,555

Source: S&P Global Market Intelligence. Standard template. Financial Sources.